03 April 2023
The WA Life Sciences Innovation Hub invites you to join the next WA MTP Sector Spotlight Series event in April, to hear from Alcolizer Technology about their road to global-scale commercialisation.
Our monthly series is an opportunity for representatives from across the MTP sector to connect, collaborate and learn about upcoming opportunities, and hear the stories and successes of WA organisations developing health and medical innovations. Join us for networking and conversation over light refreshments at the Harry Perkins Institute of Medical Research.
This month’s event shines a spotlight on Alcolizer Technology as Dr Olga Shimoni shares insights on the organisation’s road to global-scale commercialisation, on-shoring of their manufacturing (pre-covid), the pivot to COVID-19 diagnostics, transferring technology out of academic into industry and Olga’s personal reflections on leaving a research career for industry.
Dr Olga Shimoni is a Senior Scientist at Alcolizer Technology, leading R&D into a novel diagnostic test for infectious diseases.
Before moving to the industry, Dr Shimoni held the position of A/Professor and Group Leader at the University of Technology Sydney (UTS), focusing on translating innovative nanoparticle technologies into mature healthcare products, such as biosensors and in vitro diagnostics. During her academic career, A/Prof Shimoni has co-authored more than 40 research papers in high-impact journals, two book chapters and 2 patents. She actively engaged with industry partners and MedTech start-up communities to commercialise research and has been involved in establishing a start-up. Furthermore, she has successfully attracted over $5 million in research funding from various organisations, including ARC, NHMRC and philanthropy.
Alcolizer Technology is a world-leader in the field of Alcohol and other Drugs (AOD) testing and has been one of the world’s leading manufacturers of alcohol breath testing equipment for over 25 years, servicing law enforcement agencies, industry and personal users.
In 2021, Alcolizer was one of six companies to share in funding under the Government’s $30 million Commercialisation Fund, which brings together industry and researchers on job-creating projects. Alcolizer’s project focused on a new medical device called the ‘Virulizer’ in partnership with the University of Sydney. The device is a mass market saliva-based antigen test designed to detect COVID-19 in asymptomatic and symptomatic patients within 15 minutes.
Thursday 27 April 2023, from 4:30-6:00pm AWST, Ground Floor Auditorium at Harry Perkins Institute of Medical Research, 6 Verdun Street Nedlands. Register on Eventbrite.
4:30pm Informal networking (COVID restrictions permitting) at ground floor of the Perkins Institute with light breakfast
5:00pm Guided fireside chat
6:00pm Event close